Merus NVNASDAQ: MRUS

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

-   60% response rate observed among 10 evaluable patients -   F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed -   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Merus (MRUS) experienced significant movement in the last trading session with above-average volume. However, the recent trend in earnings estimate revisions may not support further upward movement in the stock in the short term.

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.